Market Cap | 12.21K | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
Income | -43.3M | Forward P/E | 0.00 | EPS next Y | - | 50D Avg Chg | -38.00% |
Sales | - | PEG | - | EPS past 5Y | - | 200D Avg Chg | -97.00% |
Dividend | N/A | Price/Book | 0.00 | EPS next 5Y | - | 52W High Chg | -100.00% |
Recommedations | 3.00 | Quick Ratio | 0.63 | Shares Outstanding | 122.08M | 52W Low Chg | - |
Insider Own | 0.92% | ROA | -106.64% | Shares Float | 120.96M | Beta | -14.54 |
Inst Own | - | ROE | -541.02% | Shares Shorted/Prior | 10.34M/8.59M | Price | 0.00010 |
Gross Margin | - | Profit Margin | - | Avg. Volume | 76,599 | Target Price | - |
Oper. Margin | - | Earnings Date | Nov 15 | Volume | 7,519 | Change | 0.00% |
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on May 18, 2023.
B. Riley Securities | Neutral | Mar 22, 22 |
HC Wainwright & Co. | Neutral | Mar 21, 22 |
Ladenburg Thalmann | Neutral | Mar 21, 22 |
HC Wainwright & Co. | Buy | Jun 1, 20 |
B. Riley Securities | Buy | Mar 18, 20 |
B. Riley Securities | Buy | Mar 13, 20 |
Credit Suisse | Neutral | Nov 8, 19 |
Credit Suisse | Outperform | Sep 6, 19 |
Baird | Outperform | Jan 18, 19 |